1. Introduction {#sec1}
===============

Colorectal cancer is the third most common cancer and the third most common cause of high mortality cancer rates in the united states \[[@B1]\]. Although the incidence of CRC is 18% higher in developed regions in comparison with lower-income areas \[[@B2]\], there is a rapid increase in developing countries in the past few decades, which makes it a major public health concern worldwide. CRC is recognized as a complex multipathway disease circled with chronic inflammation, metabolic syndrome, insulin resistance (IR), and obesity. The results from epidemiological evidence indicate that obesity is associated with increased incidence of CRC \[[@B3], [@B4]\]. Recent studies suggest that adipocyte-derived secretory factors including adiponectin, leptin, resistin, visfatin, and numerous cytokines including TNF-alpha, IL-6, and IL-10 may be the key to link obesity with CRC, although underlying mechanisms remain unexplained \[[@B5]--[@B8]\].

Resistin, produced by adipose tissue whereas it is mostly secreted from monocytes and macrophages and involved in autocrine and paracrine cell signaling \[[@B9]\], has raised considerable research interest in recent years \[[@B10]\]. It is a cysteine rich 108-amino-acid peptide with a molecular weight of 12.5 kDa, mapping to the p13.3 band of human chromosome 19 \[[@B11], [@B12]\] and circulating in low and high molecular weight forms \[[@B13]\]. As a member of resistin-like molecules (RELMs), which is a small family of secreted proteins associated with the activation of inflammatory \[[@B14]\], resistin can regulate inflammatory response, mediate metabolic disturbances and IR, promote cell proliferation, and enhance cancer progression \[[@B15]\], providing novel insights to obesity and colorectal cancer.

Although there are several systematic reviews evaluating the relationship between several adipocytokines and risk of CRC or CRA, including leptin and adiponectin \[[@B16]--[@B20]\], to the best of our knowledge, there is no meta-analysis on the associations of circulating resistin and CRC. In the past few years, some studies indicated a positive association between resistin levels and CRC \[[@B18], [@B21]--[@B28]\]; others failed to demonstrate such a relationship \[[@B29]--[@B32]\]. Seeing that controversial discrepancy, we summarized the evidence obtained from available data to assess resistin levels in patients with CRC.

2. Materials and Methods {#sec2}
========================

Since we were evaluating observational studies, we conducted this meta-analysis in accordance with the Observational Studies in Epidemiology \[[@B33]\].

2.1. Search Strategy {#sec2.1}
--------------------

A systematic literatures search from online databases including MEDLINE, EMBASE, and ISI Web of Knowledge was performed. The respective scientific studies up to November 20, 2015, were identified without language, year, or publication status restriction. Besides, we searched National Knowledge Infrastructure (CNKI) and WanFang database for Chinese literatures. The following terms were used as strategy: resistin OR adipokine OR adipocytokine OR adipocyte secreted factor (ADSF) OR FIZZ-3 OR obese protein, colorectal OR colon OR rectum, cancer OR tumor OR carcinoma OR neoplasm. Reference lists of identified literature were also checked for additional articles.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Eligible cohort and case-control studies reporting the association between serum or plasma resistin levels and colorectal cancer were included in this meta-analysis. We excluded studies as follows: (1) reviews or nonoriginal studies; (2) studies on animal or cell or tissue or genetic variation; (3) studies without controls or original data; (4) studies related to mechanism or prognosis or survival.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

The following information and data were extracted from each included study: (1) basic information such as first author\'s name, year of publication, and geographic location; (2) details of each trial, for example, study design and size, type of blood sampling, resistin detection method, and reagent; (3) characteristics of patients and controls including age, gender, BMI estimation, means, and standard deviation (SD) of resistin concentration. Two reviewers independently finished the extraction work and the disagreements were resolved by consensus or the third reviewer. Meanwhile, we systematically assessed the quality of each study with the Newcastle-Ottawa Scale (NOS) \[[@B34]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

All statistical analyses were conducted with Stata 11.0 (Stata, College Station, Texas, USA) and Review Manager 5.3 software (Cochrane Collaboration). Weighted mean differences (WMDs) and corresponding 95% confidence intervals (CIs) were calculated based on the sample size, mean, and SD extracted from eligible studies. For five studies that only provided the median and range or interquartile range of outcomes, mean and SD were estimated, as described by Hozo et al. \[[@B35]\] and Liu et al. \[[@B36]\]. The Cochran Q statistic and inconsistency index (*I* ^2^) were used for examining the heterogeneity among studies, with the statistical significance level 0.05. Considering the presence of significant heterogeneity, we applied a random effects model for pooling effect, otherwise, a fixed-effects model.

In order to explore the sources of heterogeneity, we performed subgroup analysis by geographical area, study design, study size, quality, blood sample, resistin assay method, mean age, and mean BMI. Besides, several sensitivity analyses were conducted by omitting one study at a time, excluding estimated effect sizes and studies not adjusted for BMI. Publication bias was evaluated by funnel plot, complementary with Egger\'s regression method and Begg\'s rank correlation method.

3. Results {#sec3}
==========

3.1. Search Results and Studies\' Characteristics {#sec3.1}
-------------------------------------------------

A total of 122 potential records were detected by the primary database search and 78 were left after being autodeduplicated. By reading titles and abstracts for relevance, 54 reports were excluded because they were either review articles, mechanism studies, animal studies, or irrelevant to circulating resistin. Of the 24 records selected for detailed full-text evaluation, only 10 studies fulfilled our inclusion criterion. Three studies did not measure circulating resistin levels in healthy controls. Two trials were excluded because of one provided box-plot without data to describe distribution of serum resistin concentration and the other reported only odd ratio (OR) and 95% CI of the risk of colorectal cancer; we could not get primary data although we tried to contact the authors. Besides, a Chinese study that met the inclusion criterion was added. A flow diagram of selection strategy was presented in [Figure 1](#fig1){ref-type="fig"}.

Consequently, 11 studies including 965 patients with colorectal cancer and 1325 healthy controls were identified in this meta-analysis. Among the 11 studies, one was case-cohort study conducted in USA \[[@B31]\], while the other 10 studies were of case-control design conducted either in Asia \[[@B18], [@B21], [@B23], [@B25], [@B26], [@B28]\] or in Europe \[[@B24], [@B27], [@B29], [@B32]\]. Ten of the studies were matched for age and/or gender \[[@B18], [@B21], [@B23], [@B24], [@B26]--[@B29], [@B31], [@B32]\] and 6 of them were adjusted for BMI additionally \[[@B21], [@B23], [@B24], [@B26], [@B27], [@B31]\]. The characteristics of each study were summarized in [Table 1](#tab1){ref-type="table"}. The quality assessments of 11 case-control studies were presented in [Table 2](#tab2){ref-type="table"}. The only case-cohort study \[[@B31]\] was finally awarded 7 stars based on Newcastle-Ottawa Scale (NOS) and specific assessment items were not listed.

3.2. Data Analysis {#sec3.2}
------------------

Three studies showed that patients with colorectal cancer had no significant difference in circulating resistin concentration compared to healthy controls \[[@B29], [@B31], [@B32]\], while significant increase was presented in other nine studies \[[@B18], [@B21]--[@B28]\]. The summary WMD of resistin levels between CRC patients and control group was 1.47 ng/mL (95% CI: 0.78 to 2.16), and *z*-score for overall effect was 4.19 (*p* \< 0.0001), which revealed a possibility that higher circulating resistin level was associated with higher risk of colorectal tumor. Significant heterogeneity was observed among studies and needed further analysis (*I* ^2^ = 72%, *p* \< 0.0001; [Figure 2](#fig2){ref-type="fig"}).

3.3. Subgroups/Sensitivity Analysis {#sec3.3}
-----------------------------------

We subsequently conducted subgroups and sensitivity analysis to trace the potential sources of heterogeneity. In subgroup analysis, the summary WMD of circulating resistin levels between CRC patients and healthy controls did not differ substantially by mean age, sample size, and mean BMI. Thus, heterogeneity could not be explained by those variables. However, positive association was observed between resistin levels and risk of colorectal cancer in serum samples, studies with ELISA method, low quality studies, studies of Asian origin, and case-control design, indicating the possible origin of heterogeneity. Pooled WMD of resistin levels in serum samples (WMD, 1.97; 95% CI, 1.18--2.75), studies with ELISA method (WMD, 1.68; 95% CI, 0.95--2.41), low quality studies (WMD, 1.69; 95% CI, 0.98--2.41), studies of Asian origin (WMD, 1.70; 95% CI, 1.03--2.37), and case-control design (WMD, 1.84; 95% CI, 1.51--2.18) were stronger than in plasma samples (WMD, 0.59; 95% CI, −0.39--1.57), studies with multiplex immunoassay (WMD, 0.45; 95% CI, −0.50--1.40) and high quality studies (WMD, 1.22; 95% CI, −0.33--2.78), studies of Western origin (WMD, 0.93; 95% CI, −1.20--3.05), and case-cohort design (WMD, 0.50; 95% CI, −0.52--1.52). Results of subgroups analysis are presented in [Table 3](#tab3){ref-type="table"}.

Three of 11 studies mentioned the relationship between circulating resistin levels and TNM stages of colorectal cancer. The results of those studies were inconsistent ([Table 4](#tab4){ref-type="table"}). Pooled mean differences suggested that circulating resistin levels might not be significantly different in CRC stage II--IV patients ([Figure 3](#fig3){ref-type="fig"}).

In sensitivity analysis, there was no significant difference after deleting a single study at a time and calculating pooled WMD of the remainders ([Figure 4](#fig4){ref-type="fig"}). Neither separate analysis of studies matching for BMI yielded significant associations of resistin levels and colorectal cancer risk. While removing studies for which the mean and SD were estimated \[[@B23], [@B27], [@B29], [@B31], [@B32]\], a stronger association between resistin and CRC was noted (WMD, 2.10; 95% CI, 1.25--2.95).

3.4. Publication Bias {#sec3.4}
---------------------

We did not find distinct funnel plot asymmetry, raising a low probability of publication bias ([Figure 5](#fig5){ref-type="fig"}). Egger\'s regression test (*p* = 0.34) and Begg\'s adjusted rank correlation test (*p* = 0.78) verified that possibility ([Figure 6](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

The results of this meta-analysis suggested that resistin levels were notably higher in patients with CRC than those in healthy controls, indicating that resistin levels may be positively correlated with risk of colorectal cancer, although there was significant heterogeneity among the studies. The effects of estimates were consistent for studies regardless of their sample size, mean age, mean BMI, and whether being adjusted for BMI or not. No publication bias was observed in our meta-analysis. Keeping in mind the role of resistin in linking obesity to colorectal cancer risk, as well as the inconsistent published results regarding the effect of resistin in this setting, this meta-analysis is of special importance.

Although the role of resistin in colorectal cancer is far from being elucidated, several mechanisms may be involved in explaining these outcomes. In vitro studies demonstrate that resistin has proinflammatory effects mediated by TLR4 receptor stimulation and NF-*κ*Β pathway \[[@B37], [@B38]\]. Other studies show that resistin regulates production of the matrix metalloproteinases (MMPs) and modulates the secretion of vascular endothelial growth factor (VEGF), which is considered of importance for promoting tumor invasion \[[@B39], [@B40]\]. An animal study, where the mice were dealt with to lack adipocyte-derived mouse resistin but be able to produce human resistin resulting in rapidly accelerated white adipose tissue (WAT) inflammation after the high-fat diet, indicated that resistin contributes to WAT inflammation and insulin resistance \[[@B41]\]. Furthermore, RETN (rs1862513) or -420C\>G resistin gene polymorphism is associated with decreased CRC susceptibility \[[@B29], [@B42]\].

Recently, studies demonstrate that obesity is strongly related to CRC, which is involved in several mechanisms, such as obesity-related insulin resistance, oxidative stress \[[@B43]\], adipocytokine production \[[@B44]\], and insulin-like growth factor-1 (IGF-1) \[[@B45]\]. They are all responsible for cancer promoting effects, increasing tumor cell migration, and finally leading to tumor metastasis. The overexpression of resistin results in the accumulation of intracellular lipid and then leads to obesity-mediated insulin resistance and inflammation \[[@B46], [@B47]\]. Therefore, it is widely accepted that high resistin levels are related to inflammatory conditions and malignancies \[[@B48], [@B49]\].

However, we cannot ignore the significant heterogeneity across studies in the interpretation of the findings. To investigate potential sources, we performed subgroup and sensitivity analyses. Our study suggested that BMI may not be important in explaining the heterogeneity, since effect estimates showed no difference in different mean BMI subgroup and studies whether adjusting for BMI or not. However, the stronger and more detailed estimating factor for obesity including waist circumference and waist-to-hip ratio was not available in most involved studies, so effect of visceral fat accumulation could not be checked. Furthermore, cachexia patients with advanced CRC have lower BMI, which may be a confounding factor. Notably, the low quality and case-control studies pooled stronger relationship between resistin levels and CRC. The only case-cohort study with high quality demonstrated that plasma level of resistin was not associated with CRC. The discrepancy highlights the need for well-designed prospective studies on resistin and colorectal cancer. Besides, sample type and detection method may also contribute to heterogeneity. It may be explained by the reason that circulating resistin levels are affected by different storage condition and sensibility of assays referring to the very low resistin concentration in human blood.

There are other limits which should be acknowledged in our analysis. First, because this meta-analysis is based on observational studies that have inherent bias, the causal relationship of higher resistin levels and higher risk of CRC may not exist. Second, we eventually included 11 studies and 965 CRC patients in our analysis encompassing a case-cohort study which consisted of almost half research patients; the numbers of studies classified into some subgroups were too small to perform a pooled analysis. Possibly because resistin is newly discovered, researches with large sample size are lacked. Third, the estimates of mean and SD from median and range are a cause of bias as described in sensitivity analysis results. At last, we did not rule out residual confounders that may alter resistin levels, including lifestyle parameters such as smoking, alcohol, exercise, nutritional habits, and clinicopathological features such as tumor stage, localization, and type.

In conclusion, our study suggests that circulating resistin levels in patients with CRC are significantly higher than those in healthy controls, increasing the current understanding of the association between resistin levels and risk of colorectal cancer. Given the limitations mentioned above, larger well-designed randomized studies and even experimental researches are needed to confirm the effect of resistin levels in the development of colorectal cancer.
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###### 

Characteristics of the studies included in meta-analysis.

  References                           Country       Blood sample   Study design   Case/control, number   Assay method and resource   Assay resource                  Total resistin means (ng/mL) and SD
  ------------------------------------ ------------- -------------- -------------- ---------------------- --------------------------- ------------------------------- -----------------------------------------
  Kumor et al. 2009 \[[@B24]\]         Poland        Serum          Case-control   36/25                  ELISA                       R&D Systems                     6.79 ± 2.41/3.6 ± 1.08
  Gonullu et al. 2010 \[[@B26]\]       Turkey        Serum          Case-control   36/37                  ELISA                       BioSource                       6.1 ± 3.3/4.5 ± 1.5
  Nakajima et al. 2010 \[[@B23]\]      Japan         Plasma         Case-control   115/115                ELISA                       BioVender Laboratory Medicine   4.5 (3.1--6.4)/3.1 (2.2--4.7)^a^
  Danese et al. 2012 \[[@B27]\]        Italy         Serum          Case-control   40/40                  ELISA                       Mediagnost                      5.88 (1.84--22.35)/4.94 (1.82--8.16)^b^
  Hillenbrand et al. 2012 \[[@B32]\]   Germany       Plasma         Case-control   67/60                  Multiplex immunoassay       Millipore                       10.9 (4.2--43.5)/10.8 (5.2--24.9)^b^
  Ho et al. 2012 \[[@B31]\]            USA           Plasma         Case-cohort    456/834                Multiplex immunoassay       Millipore                       12.8 (9.9--16.4)/12.3 (9.8--15.6)^a^
  Joshi et al. 2014 \[[@B18]\]         South Korea   Serum          Case-control   100/100                ELISA kit                   Adipogen                        4.9 ± 2.3/2.8 ± 1.7
  Lu et al. 2010 \[[@B28]\]            China         Serum          Case-control   30/30                  ELISA                       ADL                             7.72 ± 2.6/7.42 ± 3.72
  Tulubas et al. 2014 \[[@B21]\]       Turkey        Serum          Case-control   30/30                  ELISA                       AssayMax ELISA kit              18.77 ± 5.09/13.36 ± 6.36
  Wägsäter et al. 2008 \[[@B29]\]      Sweden        Plasma         Case-control   35/34                  ELISA                       R&D Systems                     3.95 (1.50--2.40)/5.25 (2.00--3.00)^b^
  Kosova et al. 2013 \[[@B25]\]        Turkey        Serum          Case-control   20/20                  ELISA                       Millipore Corporation           4.92 ± 2.2/3.39 ± 1.1

^a^Median (interquartile range).

^b^Media (range).

###### 

Assessment of study quality.

  Quality indicators from Newcastle-Ottawa Scale                   Kumor et al. \[[@B24]\]   Gonullu et al. \[[@B26]\]   Nakajima et al. \[[@B23]\]   Danese et al. \[[@B27]\]   Joshi et al. \[[@B18]\]   Lu et al. \[[@B28]\]   Tulubas et al. \[[@B21]\]   Wägsäter et al. \[[@B29]\]   Kosova et al. \[[@B25]\]   Hillenbrand et al. \[[@B32]\]
  ---------------------------------------------------------------- ------------------------- --------------------------- ---------------------------- -------------------------- ------------------------- ---------------------- --------------------------- ---------------------------- -------------------------- -------------------------------
  Independent validation of case definition                        Yes                       Yes                         Yes                          Yes                        Yes                       No                     Yes                         Yes                          No                         No
  Consecutive or obviously representative series of cases          No                        No                          Yes                          No                         No                        No                     Yes                         Yes                          Yes                        No
  Community controls                                               No                        No                          No                           No                         No                        No                     No                          Yes                          No                         No
  Controls have negative colonoscopy                               Yes                       Yes                         Yes                          Yes                        No                        No                     Yes                         No                           No                         No
  Study controls for age/gender                                    Yes                       Yes                         Yes                          Yes                        Yes                       Yes                    Yes                         Yes                          No                         Yes
  Study controls for BMI                                           Yes                       Yes                         Yes                          Yes                        No                        No                     Yes                         No                           No                         No
  Secure record of resistin levels with blinded interview          No                        No                          No                           No                         No                        No                     No                          No                           No                         No
  The same method of resistin measurement for cases and controls   Yes                       Yes                         Yes                          Yes                        Yes                       Yes                    Yes                         Yes                          Yes                        Yes
  The same nonresponse rate for cases and controls                 No                        No                          No                           No                         No                        No                     No                          No                           No                         No
  Score                                                            5                         5                           6                            5                          3                         2                      6                           6                            2                          2

###### 

Subgroup analysis of circulating resistin levels and colorectal cancer.

  Stratification group     Data points (*N*)   Cases   Random effects   Heterogeneity                
  ------------------------ ------------------- ------- ---------------- ---------------------- ----- ----------
  All studies              11                  965     1325             1.47 \[0.78, 2.16\]    72    \<0.0001
  Study location                                                                                      
   Western                 4                   178     159              0.93 \[−1.20, 3.05\]   83    0.0005
   Asian                   6                   331     332              1.70 \[1.03, 2.37\]    57    0.04
   USA                     1                   456     834              0.50 \[−0.52, 1.52\]   ---   ---
  Study design                                                                                        
   Case-control            10                  509     491              1.84 \[1.51, 2.18\]    70    0.0004
   Case-cohort             1                   456     834              0.50 \[−0.52, 1.52\]   ---   ---
  Sample size                                                                                         
   \<100 CRC cases         8                   294     276              1.48 \[0.38, 2.57\]    75    0.0002
   ≥100 CRC cases          3                   671     1049             1.42 \[0.55, 2.28\]    74    0.02
  Blood sample                                                                                        
   Plasma                  4                   673     1043             0.59 \[−0.39, 1.57\]   50    0.11
   Serum                   7                   292     282              1.97 \[1.18, 2.75\]    68    0.004
  Assay method                                                                                        
   ELISA                   9                   442     431              1.68 \[0.95, 2.41\]    72    0.0004
   Multiplex immunoassay   2                   523     894              0.45 \[−0.50, 1.40\]   0     0.78
  Study quality                                                                                       
   Low (NOS score ≤ 5)     7                   329     312              1.69 \[0.98, 2.41\]    62    0.01
   High (NOS score \> 5)   4                   636     1013             1.22 \[−0.33, 2.78\]   79    0.002
  Mean age, years                                                                                     
   \<60                    2                   66      67               1.15 \[0.19, 2.11\]    38    0.2
   ≥60                     9                   879     1238             1.56 \[0.65, 2.47\]    79    \<0.0001
   Not mentioned           1                   20      20               1.53 \[0.45, 2.61\]    ---   ---
  Mean BMI, kg/m^2^                                                                                   
   \<25                    1                   115     115              1.40 \[0.64, 2.16\]    73    0.01
   ≥25                     6                   665     1026             1.83 \[0.54, 3.12\]    79    0.0002
   Not mentioned           4                   185     184              1.03 \[−0.14, 2.21\]   73    0.01

###### 

Circulating resistin levels in TNM patients with colorectal cancer.

  Studies                           Sample size   Stage 0     Stage I      Stage II      Stage III     Stage IV      *p* value   Detection methods
  --------------------------------- ------------- ----------- ------------ ------------- ------------- ------------- ----------- -------------------
  Nakajima et al. 2010 \[[@B23]\]   115           1.3 ± 0.5   1.6 ± 0.5    1.5 ± 0.5     1.5 ± 0.6     1.7 ± 0.5     \<0.01      ELISA
  Gonullu et al. 2010 \[[@B26]\]    33            ---         ---          6.01 ± 3.18   7.37 ± 3.58   5.79 ± 3.96   ---         ELISA
  Kumor et al. 2009 \[[@B24]\]      36            ---         5.86 ± 3.1   6.79 ± 2.41   \>0.05        ELISA                     
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